3) These effects were accompanied with a shortening of the action potential and a dose-dependent blockade of L-type calcium current (IC 50 = 2.4x10 -8 M).
Summary

1)
This study examined the effects of SR33805, a fantofarone derivative with reported strong Ca 2+ -antagonistic properties on the contractile properties of intact and skinned rat ventricular myocytes.
2)
On intact cells loaded with the Ca 2+ -fluorescent indicator Indo-1, the application of low concentrations of SR33805 enhanced the amplitude of unloaded cell shortening and decreased the duration of cell shortening. Amplitude of the Ca 2+ transient was also decreased.
3) These effects were accompanied with a shortening of the action potential and a dose-dependent blockade of L-type calcium current (IC 50 = 2.4x10 -8 M).
4)
On skinned cardiac cells, the application of a low SR33805 concentration (10 -8 M)
induced a significant increase in maximal Ca 2+ -activated force at the two-tested sarcomere lengths, 1.9 and 2.3 µm.
5) The application of a larger dose of SR33805 (10 -6
-10 -5 M) induced a significant leftward shift of the tension-pCa relation that accounts for Ca
2+
-sensitization of the myofilaments, particularly at 2.3 µm sarcomere length.
6)
In conclusion, despite its strong Ca 2+ -antagonistic properties SR33805 increases cardiac cell contractile activity as a consequence of its Ca 2+ -sensitizing effects. These effects are attributable to both an increase in the maximal Ca 2+ -activated force and a -N-methyl-amino-propoxyl]-4-benzenesulfonyl]-2-isopropyl-3-methyl-1-indole) is structurally related to fantofarone and classified as a substituted indole. It has several distinct and important differences, and in vivo studies have shown that SR33805 possesses a different profile of activity in terms of contractile activity compared with fantofarone and other Ca 2+ channel blockers (Chatelain et al., 1993) . This compound binds to alpha 1 -subunit of the L-type Ca 2+ channels with a high affinity (K D value = 20 pM) but at a site different from the binding site of the classical Ca 2+ channel blockers (Chatelain et al., 1994) . It potently inhibits the Ca 2+ channel in mouse cardiac myocytes in primary culture with IC 50 ranging from 4.1 to 33 nM (Romey et al., 1994) . In spite of this potent calcium inhibitor effect, Chatelain et al. (1993) reported that SR33805 had a weak negative inotropic effect on electrically-evoked contraction in rabbit isolated atria. The IC 50 of the negative inotropic effects on rabbit papillary muscles were 38.0 and 0.25 µM for SR33805
length-dependent Ca
Introduction
and verapamil, respectively. SR33805 was also shown to induce vasorelaxation of rat and rabbit basilar artery strips (Chatelain et al., 1993) . A comparison of IC 50 values for cardiac and smooth muscles indicates that SR33805 is highly selective to vascular tissue compared with other Ca 2+ channel blockers such as verapamil, diltiazem or nifedipine. This led the authors to suggest that the effects of SR33805 depend mainly on membrane potential (Chatelain et al., 1993) . However, it has been recently reported on porcine coronary artery that SR33805 reduces Ca 2+ transient but increases Ca 2+ sensitivity of the myofilaments by an increase of MLC phosphorylation such that force development resisted to the reduction by SR33805 of intracellular Ca 2+ release (Ieiri et al., 2000) . The concentration of SR33805 required to inhibit contraction was approximately 10 times higher than that required to inhibit [Ca 2+ ] i elevation.
4
Myocardial contractility can be improved by increasing Ca 2+ concentration or by increasing sensitivity of myofilaments to Ca 2+ (Lee & Allen, 1997) . The latter mechanism has been proposed to be mainly responsible for the Frank-Starling mechanism in which preload of the heart enhances contractile forces. Despite complex relations between ventricular pressure and myocyte tension as well as between volume and sarcomere length, ultimately the volumeend systolic pressure relation depends on the number of strong force-generating cross-bridges as sarcomere length changes. Thus, the developed tension by isolated cardiac preparations was found to increase in parallel with an increase in muscle length. The same is true at the single cell level (Vannier et al., 1997) . It is admitted that contractility of the failing heart is reduced at the organ and cellular levels. The volume or length sensitivity of the heart or cardiomyocytes, respectively in cardiac diseases is more controversial from being absent (Schwinger et al., 1994) to reduced (Anand et al., 1997; Holubarsch et al., 1996) . Thus cell length is an important parameter to consider when strategies to restore contractility are investigated.
Besides these intrinsic properties, the responsiveness of contractile proteins can also be increased by Ca 2+ -sensitizing drugs. This new class of inotropic agents has the advantages of avoiding the problems associated with Ca 2+ overloading such as arrhythmias by glycosides and catecholamines and of enhancing force production without increasing energy utilization.
However most of these agents including EMD57033 or CGP48506 that sensitize the myofilaments to Ca 2+ by promoting the actin-myosin interaction, significantly reduce the length-dependency (from 1.9 to 2.3 µm sarcomere length) of Ca 2+ activation (Arteaga et al., 2000) . This will attenuate the Frank-Starling mechanism and consequently these drugs will be less effective on diseased hearts. -sensitizing effect that occurred mainly at high sarcomere length.
Methods
Ventricular myocyte isolation
Cardiac ventricular cells were isolated from 200-250 g male Wistar rats as previously described (Cazorla et al., 1999) . Briefly, rats were anaesthetized by intraperitoneal injection of pentobarbital (200 mg/100 g). The heart was perfused retrogradely with a Ca 2+ -free Hanks-HEPES buffered solution for 5 min at 37°C and then an enzyme-containing solution for [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] min (see Solutions). The ventricles were gently dissociated with forceps in the same medium without enzyme. The cells were then filtered and further incubated for 15 min. Cells were washed several times in a solution containing 0.3 mM Ca
2+
. Finally myocytes were kept in a medium containing 1 mM Ca 2+ and 0.5% bovine serum albumin (BSA). After collagenase treatment all solutions contained protease inhibitors (PMSF, leupeptin and E-64 (transepoxysuccinyl-l-leucine-guanidobutylamide); (see Cazorla et al., 2001) ). 
Mechanical recording and sarcomere length measurement
Myocytes were skinned for 6 min at room temperature in a relaxing solution (pCa 9, see below) containing 0.3% vol/vol Triton X-100 and protease inhibitors (see above). Cells were then rinsed twice with the same solution without Triton X-100 and maintained at 4°C. The experimental apparatus and cell attachment procedure were similar to those described previously (Cazorla et al., 1999) . Myocytes were observed through an inverted microscope (Diaphot, Nikon, Boulogne, France). Both ends of skinned myocytes were glued to a thin glass rod with optical glue (NOA 63, Norland products Inc, North Brunswick, NJ) that was polymerized by UV illumination for 3 min. Sarcomere length was determined online at 50 Hz by using a Fast Fourier Transform algorithm (FFT) on the digitized striation images of the attached cell (Gannier et al., 1993 Compliance of the strain gauge was 0.1 µm.µN -1 and unloaded resonance frequency was 500
Hz (Vannier et al., 1997) . Force measurements were low-pass filtered at 100 Hz and recorded Slack sarcomere length (SL) was determined for each cell before attachment and ranged between 1.82 and 1.9 µm. Cells were first maximally activated with a pCa 4.5 solution to test the quality of the attachment and recovery to baseline. Passive force was determined by stretching the cell using a stepper motor driven micromanipulator (MP-285, Sutter instrument company, Novato CA, USA) at a speed of 0.1 length.sec -1 . The force-pCa relationships were established on each cell at two sarcomere lengths, 1.9 and 2.3 µm. For relative tension-pCa curves, active forces at submaximal activations were normalized to that produced at pCa 4.5 8 at the same SL. Force slightly diminished with the number of Ca 2+ applications; the mean reduction for maximal force was 6.3 ± 2.0% (n = 28) during the establishment of two successive force-pCa curves. The relation between force and pCa was fitted to the following
, where n H is the Hill coefficient and pCa 50 , pCa for half-maximal activation, equals -(log K)/n H .
Electrophysiology
The electrophysiological experiments were performed using the whole-cell patch- Experiments were performed at room temperature (25°C). SR33805 was a gift of Dr P.
Gautier (Sanofi -Synthelabo, Montpellier, France).
Statistics
Data are presented as mean ± SEM (n = number of cells studied). Significant differences were assigned to selected parameters using paired or unpaired Student's t-test or 1-way ANOVA (as appropriate) with P < 0.05.
Results
Effect of SR33805 on Ca 2+ transient and shortening of intact cardiomyocytes
The effects of SR33805 were first investigated by measuring both the variations in intracellular Ca 2+ concentration and shortening in isolated rat ventricular cardiomyocytes using a multiphoton laser scanning microscope (Figure 1 ). In intact myocytes the application of SR33805 (from 10 -10 to 10 -7 M) produced a concentration-dependent decrease in the amplitude of the Ca 2+ transient. This effect was statistically significant at 10 -8 M and 10 -7 M with a decrease of 14% and 17%, respectively. This result is in accordance with the Ca 2+ channel blockade properties of SR33805 previously observed in mouse cardiomyocytes in culture (Romey et al., 1994 ) that we confirmed in freshly isolated adult ventricular myocytes ( Figure 2B ). Furthermore the time course of the Ca 2+ transient was hardly affected (not shown). Cell shortening characteristics were also modified by SR33805. The amplitude of cell shortening was significantly reduced at 10 -7 M SR33805 by 18% compared with control conditions. However surprisingly, cell shortening increased on applying SR33805 from 10 -10 to 10 -8 M. The latter dose induced a significant increase in cell shortening by 14%.
Consequently, contractile efficiency (ratio between cell shortening and Ca 2+ transient amplitude) increased by 36% after treatment with 10 -8 M SR33805. The duration of the cell shortening was significantly reduced particularly the duration at 10% of maximal shortening ( Figure 1B ).
Effect of SR33805 on action potential and calcium current of intact rat cardiomyocytes
To test whether the increase in contractile force could be in part attributable to a prolongation of the electrical activity, the effects of SR33805 were investigated on action potential recorded on single cells under current clamp conditions. SR33805 (10 -8 -10 -6 M)
slightly but significantly reduced the action potential duration at half-repolarization (APD 50 ).
This effect on the repolarization phase was maximal at 10 -7 M (24%, Figure 2A ). This result could be related to L-type Ca 2+ channel blockage previously observed by Romey et al. (1994) in mouse cardiac cells in primary culture. To test this hypothesis we measured L-type Ca 2+ current under voltage clamp conditions on rat adult ventricular myocytes by applying a test potential to +10 mV from the holding of -80 mV. Cells were exposed to a fixed concentration of SR33805 until a steady state effect on the Ca 2+ current was reached within 2 minutes. The Ca 2+ current decreased as SR33805 concentration was increased from 10 -9 to 10 -6 M. The dose -response curve for this inhibition is represented on Figure 2B (lower panel). The IC 50 value of the blockade of I CaL by SR33805 was 2.4x10 -8 M in rat ventricular cells, a value close to the one found in other cell types (Romey et al., 1994) .
Effect of SR33805 on mechanical properties of skinned cardiomyocytes
An increase in contractile activity while I Ca is partially blocked could be due to a direct interaction of SR33805 on the contractile machinery like observed in coronary artery (Ieiri et al., 2000) . We first examined general effects of SR33805 on cell stiffness, sub-maximal and maximal Ca 2+ -activated tension as well as reversibility of the effects on skinned myocytes.
Sarcomere length and passive tension were measured in skinned myocytes by two protocols:
1) imposing a ramp using a stepper motor driven micromanipulator at a speed of 0.1 length/sec and 2) by manually stretching the cell with steps of 0.1 µm SL from resting SL to 2.45 µm SL and allowing for stretch relaxation. Figure 3B shows steady-state passive tension-SL relationships in the absence and presence of SR33805. Values of passive tension developed at each investigated SL were similar to those previously observed (Cazorla et al., 2000; Yamasaki et al., 2002) and were unaffected by SR33805. When cells were submaximally activated (pCa 6.2) at 2.3 µm SL, active force was significantly higher in the presence of SR33805 ( Figure 3C ). This increase in force was fully reversible. Maximal Ca 2+ -activated force was rather decreased with successive applications as a consequence of the rundown generally observed and did not show marked change in the presence of the compound. Figure 3D summarizes the positive effects of 10 -6 M SR33805 on the active tension elicited at pCa 6.2 relative to maximal Ca 2+ -activated tension.
To investigate more specifically the effects of SR33805 on the contractile properties, a series of experiments was carried out using skinned myocytes at two controlled SL to obtain the following informations: 1) changes in tension development, 2) changes in myofilaments Ca 2+ sensitivity, 3) alterations in myofilaments cooperativity as determined by Hill coefficients, and 4) the effect on SL-dependent Ca 2+ activation. In these experiments, the effects of SR33805 were checked on cardiomyocytes held at either 1.9 or 2.3 µm SL by applying for short periods the activating solution at various [Ca 2+ ] in the absence or presence of SR33805. To determine active force, passive force before activation was subtracted from total force during Ca 2+ -activation. To account for run-down of force during supra-maximal activation and to allow comparison between groups (with or without drug) only two full tension-pCa relationships were established firstly at 1.9 µm SL then at 2.3 µm SL. Figure 4A illustrates two series of tension recordings elicited in skinned cardiomyocytes held at 1.9 µm SL in control solution and in the presence of 10 -8 M SR33805. In the presence of the drug, force was increased only at the lowest pCas. In control conditions, the averaged active 13 tension-pCa relationships demonstrate a characteristic leftward shift when stretching from 1.9 to 2.3 µm SL (Cazorla et al., 1999; Cazorla et al., 2001 ) ( Figure 4B ). As already reported, the maximal Ca
2+
-activated forces were similar at both SL while the Hill coefficient, n H increased with SL. The pCa 50 increased from 5.74 ± 0.03 to 6.13 ± 0.03 pCa units with lengthening. In the presence of 10 -8 M SR33805, both active tension-pCa relations, established at 1.9 and 2.3 µm SL, exhibited a marked increase in maximal tension by 37% and 29%, respectively ( Table   1 ). The relative tension-pCa curves were nearly superimposed ( Figure 4C ).
A high dose of SR33805 (10 -5 M) had no significant effect on the maximal Ca 2+ -activated tensions at both SL ( Figure 5 ). The tension-pCa relation was unaffected at short SL while pCa 50 increased at 2.3 µm SL from 6.13 ± 0.03 to 6.25 ± 0.02 pCa units demonstrating an increase in myofilament Ca 2+ sensitivity (Table 1 ).
The Hill coefficients were not significantly different in the presence of SR33805.
Despite the lack of statistical differences Hill coefficients tended to increase in the presence of low concentration of SR33805 at both SL and to decrease at long SL with 10 -5 M SR33805 (Table 1) . These changes in molecular cooperativity could influence at least in part the Ca 2+ sensitivity of the contractile machinery. -activated force at low SR33805 concentration and at higher drug concentration from a leftward shift of the tension-pCa relation that occurs mostly at the longer SL.
The present study revealed that SR33805 is both, a Ca 2+ channel blocker ( Figure 2B) and a myofilament Ca 2+ sensitizer ( Figure 6B (Solaro et al., 1993) or to a decrease in the probability of the transition from the force-generating strong-binding states to the weak-binding states (Vannier et al., 1997) . This is accompanied by a reduction in tension cost i.e. more force produced by unit of energy consumed (Popping et al., 1996) . In skinned cardiomyocytes, low concentrations of SR33805 increase the maximal Ca 2+ -activated force without significantly altering the Ca 2+ sensitivity of the myofilaments. Ca 2+ sensitivity is enhanced only at higher concentrations, at which the effect on maximal force is less. Altogether these effects are rather similar to those reported for EMD 57033 and MCI 154 although a detailed analysis of changes in cross-bridge kinetics has not been attempted in this work.
Multiple studies of the length-dependent behavior of intact cardiac muscles, isolated cardiomyocytes and various types of skinned preparations have been performed. However the detailed molecular interactions that adjust molecular motor function to myocyte length remain unclear. According to Fuchs and Wang (1996) interaction was based on a length-dependence of strong-binding actin-myosin interactions rather than length itself (Fuchs & Smith, 2001) . In more recent studies, Cazorla et al. (1999; reported in single skinned cardiomyocytes that the Ca 2+ sensitivity is correlated with passive tension rather than SL with a major role for titin that accounts for most of the elasticity of the striated fibers. It is interesting to note that the Ca
-sensitizing effect of SR33805 is length-dependent with very weak effects on cells held near slack length and with main effect at optimal SL. The positively length-dependent Ca
-sensitizing effect of SR33805 suggests that the Frank-Starling relation is steeper in the presence of the drug. This is contrary to the blunting of the length-dependent Ca 2+ activation of force in myofilaments reported for EMD57033, CGP-48506 and calmodizilium (Arteaga et al., 2000) . The latter drug sensitizes the myofilaments at 1.9 µm SL and desensitizes them at 2.3 µm. This stresses out the need to study Ca 2+ sensitizers at various controlled sarcomere lengths and not only on cell shortening in order to evaluate the effects of these drugs on the Frank-Starling mechanism. Besides the Ca 2+ -sensitizing effect per se, such an increase in length-dependence induced by SR33805 could be anticipated to be favorable to rescue contraction of diseased hearts particularly in relation with myocardium dilatation. The length-dependent increase in Ca 2+ activation induced by SR33805 cannot be attributed to changes in lateral spacing nor in diastolic tension since the effects occur without changes in passive tension of skinned cells ( Figure 3B ). It would be interesting to check whether the Ca 2+ -sensitizing effects are accompanied by increase in the phosphorylation of the myosin light chains as reported in smooth muscle (Ieiri et al., 2000) .
The benefit of using Ca 2+ -sensitizers during heart failure could be limited by a worsening of diastolic relaxation associated to an increase in diastolic force impairing ventricular filling. Thus EMD 57033 has been shown to increase time to 80% relaxation and diastolic force especially in failing human myocardium (Hajjar et al., 1997 ) possibly due to the major leftward shift of the tension-pCa curves that occurs at both 1.9 and 2.3 µm SL (Arteaga et al., 2000) . Rather in the presence of SR 33805, the amplitude and more clearly the duration of cell shortening of intact myocytes were accelerated ( Figure 1B ).
Another limitation for using Ca 2+ sensitizers is their potentiality to inhibit PDE activity that increases cAMP. Mimicking beta-adrenergic stimulation would induce : 1) proarrhythmic effects, 2) desensitization of Ca 2+ activation through TnI phosphorylation. The latter was observed in particular with pimobendan (Lee et al., 1989) and recently with levosimendan in human failing myocardium (Brixius et al., 2002) . SR33805 that demonstrates poor inhibition of the calmodulin-dependent PDE (IC 50 = 2.10 -7 M, Dr D. Nisato personal communication) should be devoid of this pro-arrhythmic effect. This is in accordance with the negative chronotropic effect reported on rabbit isolated atrial preparations (Chatelain et al., 1993) and with the lack of change of Ca 2+ sensitivity at 1.9 µm SL in our study.
In conclusion, the poor negative inotropic effects of this highly potent Ca 2+ -channel antagonist initially reported (Chatelain et al., 1993) Table 1 for contractile parameters. being the EC 50 , A1 and A2 the minimal and maximal delta pCa 50 respectively, solid line).
Dashed line and gray band represent mean delta pCa 50 and its SEM measured in control conditions, respectively.
